-
Product Insights
NewLikelihood of Approval Analysis for Skin And Skin Structure Infections (SSSI) Caused By Bacteria
Overview How likely is it that the drugs in Skin And Skin Structure Infections (SSSI) Caused By Bacteria will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Skin And Skin Structure Infections...
-
Thematic Analysis
Rare Disease ​Pipeline Analysis ​Landscape, 2023
This report investigates the Rare Disease ​Pipeline Analysis ​Landscape in 2023 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize these trends within your sector.
-
Company Insights
Innovation and Patenting activity of Incitec Pivot Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Incitec Pivot Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Imatinib Mesylate in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib Mesylate in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib Mesylate in Pulmonary Arterial Hypertension Drug Details: Imatinib mesylate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Renzapride in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Renzapride in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Renzapride in Parkinson's Disease Drug Details: Renzapride (ATL-1251, BRL-24924) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Mantle Cell Lymphoma Drug Details: Nemtabrutinib (ARQ-531) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in B-Cell Non-Hodgkin Lymphoma Drug Details: Nemtabrutinib (ARQ-531) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Follicular Lymphoma Drug Details: Nemtabrutinib (ARQ-531) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in B-Cell Chronic Lymphocytic Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in B-Cell Chronic Lymphocytic Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in B-Cell Chronic Lymphocytic Leukemia Drug Details: Nemtabrutinib (ARQ-531)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...